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BACKGROUND: Quantifying the asbestos-related lung cancer burden is difficult in the presence of this disease’s multiple causes.
We explore two methods to estimate this burden using mesothelioma deaths as a proxy for asbestos exposure.
METHODS: From the follow-up of 55 asbestos cohorts, we estimated ratios of (i) absolute number of asbestos-related lung cancers to
mesothelioma deaths; (ii) excess lung cancer relative risk (%) to mesothelioma mortality per 1000 non-asbestos-related deaths.
RESULTS: Ratios varied by asbestos type; there were a mean 0.7 (95% confidence interval 0.5, 1.0) asbestos-related lung cancers per
mesothelioma death in crocidolite cohorts (n¼ 6 estimates), 6.1 (3.6, 10.5) in chrysotile (n¼ 16), 4.0 (2.8, 5.9) in amosite (n¼ 4) and
1.9 (1.4, 2.6) in mixed asbestos fibre cohorts (n¼ 31). In a population with 2 mesothelioma deaths per 1000 deaths at ages 40–84
years (e.g., US men), the estimated lung cancer population attributable fraction due to mixed asbestos was estimated to be 4.0%.
CONCLUSION: All types of asbestos fibres kill at least twice as many people through lung cancer than through mesothelioma, except for
crocidolite. For chrysotile, widely consumed today, asbestos-related lung cancers cannot be robustly estimated from few
mesothelioma deaths and the latter cannot be used to infer no excess risk of lung or other cancers.
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Asbestos is an established human carcinogen, the major effects
being on cancers of the lung and mesothelioma of the pleura and
peritoneum (IARC, 1987). Inhalation of asbestos fibres predomi-
nantly occurs during occupational exposure including in mines,
construction, shipyards, railway and textile industries. Restrictions
or bans on the use of certain asbestos fibres were introduced in the
United States and Europe from the 1980s onwards, but latency
periods of several decades mean that the mesothelioma epidemic is
yet to peak. In 2000, an estimated 43 000 malignant mesotheliomas
worldwide were due to occupational exposures (Driscoll et al,
2005), the largest absolute burdens being in the United States,
Australia, Japan, New Zealand and Western Europe (Peto et al,
1999). Global asbestos (chrysotile) consumption was 2.3 million
tonnes in 2003, predominantly in the lower income countries
(Virta, 2006). The asbestos-related lung cancer (ARLC) burden is
more difficult to quantify as most lung cancers are not attributable
to asbestos, unlike for mesothelioma (Bianchi and Bianchi, 2007).
ARLCs occur on top of varying lung cancer incidence rates and
they are not clinically distinguishable from those not caused by
asbestos. Furthermore, reliable population-based data on asbestos
exposure (by fibre type, length, age at exposure, intensity) and
associated relative risks are not known precisely, preventing the
calculation of population attributable fractions (PAFs).
We present two methods to estimate the relationship between
ARLC deaths and mesothelioma deaths, using the latter as a proxy
for asbestos exposure. The first is the ratio of absolute excess lung
cancer deaths to mesothelioma deaths. However with a synergistic
interaction between asbestos and smoking on lung cancer, the
ARLC burden will be particularly large in settings where smoking
rates are high, thus a more appropriate ratio may be a relative
effect on lung cancer to the absolute effect on mesothelioma. Using
published cohorts of asbestos-exposed workers, we summarise
these two ratios by asbestos type to gauge the magnitude of the
population-level ARLC burden in different countries.
MATERIALS AND METHODS
Ratio estimates
We estimated the ratio of asbestos-related lung cancers to
mesothelioma deaths from asbestos cohorts. Two ratios were
calculated for each cohort. Method 1: the absolute ratio (R1) of the
absolute number of ARLC deaths to mesothelioma deaths is
estimated by R1¼ (OLCELC)/OM, where O and E refer to the
observed deaths and expected deaths in the absence of asbestos,
with subscripts LC and M referring to lung cancer and
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mesothelioma, respectively. ELC was estimated as OLC/SMR, the
SMR being the standardised mortality ratio for lung cancer,
which was usually provided. Method 2: the proportional ratio (R2)
is the ratio of the excess lung cancer percentage for every
mesothelioma death in 1000 non-asbestos-related deaths,
R2¼ [100 (OLCELC)/ELC]/[1000OM/Eall], where Eall refers to
expected deaths from all causes in the absence of asbestos,
estimated as observed deaths minus (excess lung cancersþ
mesotheliomas) (¼Oall(OLCELC)OM). We assumed no
expected mesothelioma deaths in the absence of asbestos. Note
R2¼R1Eall/(10ELC).
Given a particular type of asbestos exposure, ratio R1 will only
be constant in populations with similar background smoking and
lung cancer incidence rates if there is a proportional increase in
lung cancer risk associated with exposure (i.e., constant relative
risk). As lung cancer incidence rates vary between countries and
over time, the ratio of the relative effect on lung cancer to the
absolute effect on the mesothelioma mortality rate may be more
constant. We attempt to estimate this in ratio R2. Its numerator is
the excess relative risk percentage. The denominator would ideally
be an age-standardised mesothelioma mortality rate, but as this
rate was rarely reported in included cohorts, the number of
mesothelioma deaths per 1000 non-asbestos-related deaths (Eall)
was used as a correlate. Thus R2 is the excess lung cancer relative
risk (expressed as a percentage) for every mesothelioma death in
1000 non-asbestos-related deaths.
Included studies and data extraction
Asbestos cohorts were identified via a PubMed search, last updated
on 1 September 2011, of all articles containing the MeSH terms
‘Neoplasms’, ‘Cohort Studies’ and ‘asbestos’, yielding 425 results.
Reference lists of retrieved articles and previous relevant reviews
were also checked for omissions (Hodgson and Darnton, 2000;
Boffetta, 2007). For the British Asbestos Survey, data were extracted
from an online report (Harding, 2010). Eligible studies included were
those with (i) at least 100 subjects, (ii) certain asbestos exposure (not
just probable such as in environmental settings) and (iii) observed
and expected (based on country-level rates or an unexposed cohort)
mesothelioma and lung cancer mortality or incidence for the same
follow-up period. Cohorts consisting entirely of asbestosis or pleural
disease patients were not included. For cohorts with multiple
publications, the most informative recent one was included. From
each included publication we extracted information on cohort
characteristics, asbestos fibre type (crocidolite/chrysotile and
crocidolite/pure or predominantly chrysotile/amphiboles includ-
ing amosite/mixed or unspecified), industry, cause of death
ascertainment, whether lung cancer SMRs were adjusted for
smoking (or whether smoking prevalence was comparable with
that of the reference population), total number of deaths and
observed and expected deaths from lung cancer and mesothelioma.
Incidence data were used if mortality data were not available (not
contributing to R2). Expected deaths were usually estimated by
authors from population-level age-sex-period-specific mortality
rates. For the Great Britain Asbestos Survey, excess lung cancers
were calculated from proportional mortality ratios rather than
SMRs in order to minimise confounding by smoking (Harding,
2010). Where appropriate, mortality was based on best evidence
rather than death certificate only. In some instances only pleural
mesotheliomas were recorded (indicated in tables).
As our aim was to summarise the overall association between
the ARLC and mesothelioma mortality to reflect estimates of the
average association effect, we did not carry out a meta-regression
of all possible factors that might affect an individual ratio (other
than asbestos type and confounding by smoking). This average
association is useful because a mesothelioma burden at the
population level arises from differing exposure conditions, as
reflected in those from the various cohorts included.
Statistical methods
Extracted data were used to calculate R1 and R2 as defined.
Estimates of R1 were plotted by asbestos type, with the variance of
log(R1) estimated as (1/ELCþ 1/EM) and for R2 as (1/ELCþ 1/OMþ
1/Oall). Summary values of R1 and R2 and of SMRs for lung
cancers were obtained from a random-effects meta-analysis
implemented in STATA version 11. Meta-regression models were
used to examine whether the ratio estimates systematically differed
between studies, where smoking was controlled for or not. To
evaluate which of the ratios R1 and R2 was most appropriate, we
assessed which one explained a greater proportion of the variation
when regressing the numerators on the denominators of the
respective ratios, weighted by the inverse of the appropriate
variances given above.
To apply the ratio estimates to external larger popula-
tions, ARLCs were calculated using method 1, as R1 times the
number of mesothelioma deaths (R1OM), or using method 2,
PAFs for lung cancer due to asbestos were calculated as
(1þ 0.1Oall/(R2OM))1. Using these results, we calculated
PAF ranges for men aged 40–84 years during years 2001–2005,
using the WHO mortality database for selected countries with
mortality data coded to ICD-10 (WHOSIS Mortality Database
ICD-10, 2009).
Population attributable fraction estimates were based firstly on
ratio estimates as provided in Tables 1 and 2, and thereafter on
ratio estimates corrected for smoking if smoking had not been
accounted for. The correction applied was to reduce ratio estimates
by 25% if smoking had not been taken into account, which
corresponds to the degree of positive confounding in the lung
cancer SMR, resulting from a smoking prevalence of 70% in the
asbestos cohort compared with 50% in the general population and
a smoking relative risk of 10. This is likely to be an exaggerated
correction and thus possibly underestimates ratio and PAF
estimates.
RESULTS
Ratio estimates
Fifty five publications were included, from which 68 risk estimates
were reported, 6 for crocidolite, 8 for crocidolite and chrysotile, 14
for predominantly chrysotile, 4 for amosite and 32 to mixed or
unspecified asbestos fibres (Table 1, with an extended version in
online Supplementary Table 1). In total, follow-up included over
67 194 deaths, of which 1963 were from lung cancer and 1962 from
mesothelioma. Most studies were conducted in North America or
Europe, with only seven in other regions (Japan, Australia, China
and South Africa). The two largest cohorts were the insulation
workers’ union of the United States and Canada (n¼ 17 000), and
the Great Britain Asbestos Survey of over 98 000 registered
asbestos workers (Selikoff and Seidman, 1991; Harding, 2010).
Lung cancer SMRs for 78% of cohorts were not adjusted for
smoking, other than in a few studies where internal analyses
comparing exposed to unexposed subjects adjusted for smoking
and in certain cohorts smoking prevalence of workers was noted to
be comparable (or not) to that of the general population. We used
the proportional mortality ratio in the British Asbestos survey in
an attempt to get closer to a smoking-adjusted SMR (estimates 66
and 67).
Figure 1 plots absolute and relative lung cancer excess vs
mesotheliomas, that is, the numerator and denominators of ratios
R1 and R2, by asbestos type. Note that axes for each subplot are on
different scales, particularly for mesothelioma because of greatly
varying mesothelioma-producing potential of the different fibres.
The line on each plot corresponds to two excess lung cancer deaths
per mesothelioma death, that is, this is the same ratio across
graphs to aid comparison.
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Table 1 Crocidolite, chrysotile and amosite asbestos cohorts providing estimates of lung cancer and mesothelioma mortality, by asbestos type
No. Cohort description (reference) N
%
Male
Smoking
adjustment
Total
deaths
Lung
cancer
deaths
(OLC)
Lung
cancer
SMR
Mesothelioma
deaths (OM)
Ratio
R1
Ratio
R2
Crocidolite
1 Canadian gas mask canisters (McDonald and McDonald, 1978) 199 NK N 55 7 2.92 9 0.5 0.9
2 Nottingham gas masks, UK (Jones et al, 1980) 951 0 N 166 12 1.90 17 0.3 0.8
3 Leyland gas masks UK. Crocidolite, some chrysotile (Acheson et al,
1982)
757 0 N 219 13 2.10 5 1.4 4.6
4 South African crocidolite mines (Sluis-Cremer et al, 1992) 3430 100 N 423 27 2.03 20 0.7 2.0
5 Tuscany rail construction Italy (Battista et al, 1999) 734 100 N 199 26 1.24 5 1.0 0.9
6 Wittenoom mine/mill, Australia (Musk et al, 2008) 6943 100 C 2408 281 2.60 222 0.8 1.5
Chrysotile and crocidolite
7 Rochdale textile workers, UK. Chrysotile, 5% crocidolite during
1932–1968 (Peto et al, 1985): men, 20+ years employment
starting o1933
145 100 N 123 20 3.61 7 2.1 3.7
8 As for 7: Rochdale women, 10+ years employment after 1933 283 0 N 49 4 2.11 0 No meso.
9 As for 7: Rochdale principal cohort, men first employed 41933 3211 100 N 1113 132 1.31 11 2.9 3.1
10 New Orleans cement Plant 2, USA (Hughes et al, 1987) 3594 100 C 874 107 1.44 4 8.2 9.2
11 Vocklabruck cement workers, Austria (Neuberger and Kundi, 1990) 2816 Both A 540 49 1.04 4 0.5 0.6
12 Ferodo friction factory, UK. Predominantly chrysotile, crocidolite
use for a short period (Berry, 1994)
13 450 68 N 2577 241 0.99 13 0.2 0.2
13 North Israel cement workers, 90% chrysotile, 10% crocidolite
(Tulchinsky et al, 1999)
3057 100 N — 34 1.26 21 0.3 —
14 Norwegian asbestos cement factory. Chrysotile, 8% amphiboles
(Ulvestad et al, 2002)
545 100 N — 33 3.1 18a 1.2 —
Chrysotile (pure or predominantly)
15 Blackburn gas masks, UK. Pure chrysotile (Acheson et al, 1982) 570 0 N 177 6 1.25 1 1.2 4.4
16 Wales cement workers. After 1936, chrysotile only. Before 1936,
some crocidolite used (Thomas et al, 1982)
1970 100 N 351 22 0.85 2b 1.9 2.6
17 Connecticut friction industry, USA. Pure chrysotilec (McDonald
et al, 1984)
3531 100 N 803 73 1.49 0 No meso.
18 Swedish cement workers. Chrysotile predominantly,o1% amosite/
crocidolite during short periods (Ohlson and Hogstedt, 1985)
1176 100 C 220 11 1.22 0 No meso.
19 Tamworth cement workers, UK. Chrysotile, with amosite used
during 4 months out of 42 years (Gardner et al, 1986)
2167 70 N 486 41 0.97 1 1.4 1.6
20 Balangero mine, Italy. Pure chrysotile (Piolatto et al, 1990) 1058 100 N 427 22 1.11 2a 1.1 2.2
21 Quebec, Canada: Quebec asbestos factory, chrysotile (Liddell et al,
1997)
792 100 N 508 49 1.34 5 2.5 3.6
22 As for 21: Thetford company 3, chrysotile and tremolite 4732 100 N 3080 280 1.45 21 4.1 7.2
23 As for 21: Thetford company 4, chrysotile+tremolite 368 100 N 267 25 1.65 2 4.9 9.5
24 As for 21: Quebec asbestos mine/mill, chrysotile 4503 100 N 2924 253 1.29 8 7.1 11.8
25 Chongqin asbestos workers, China. Pure chrysotile, tremolite
content uncertain (Yano et al, 2001)
515 100 A 132 22 6.64 2 9.3 31.4
26 South Carolina textile workers, USA. Chrysotile, o0.01%
crocidolite (Hein et al, 2007)
3072 59 C 1961 198 1.95 3 32.2 58.9
27 North Carolina textile plants, USA. Predominantly chrysotile, with
some amosite in plant 3 (Loomis et al, 2009)
5770 69 N 2583 277 1.96 8d 16.9 29.1
28 Greece asbestos cement factory. Chrysotile with 0.5% amphibole
contamination (Sichletidis et al, 2009)
317 100 N 52 16 1.71 0 No meso.
29 Chrysotile miners, China (Wang X et al, 2011) 1080 100 A 343 50 4.61 0 No meso.
30 Chrysotile textile workers, China (Wang XR et al, 2011). Medium-
and high-exposed groups compared with low-exposed group
461 100 A 207 46 1.83 2 10.4 7.6
Amosite
31 Uxbridge amosite insulation, UK (Acheson et al, 1984) 4820 100 N 422 57 1.96 5 5.6 7.5
32 Paterson amosite asbestos factory, NJ, USA (Seidman et al, 1986) 820 100 N 593 98 4.78 17 4.6 11.1
33 South African amosite mines (Sluis-Cremer et al, 1992) 3212 100 N 648 26 1.38 4 1.8 6.1
34 Tyler pipe insulation, amosite, TX, USA (Levin et al, 1998) 1130 100 N 222 35 2.78 6 3.7 5.7
Anthophyllite and vermiculite
35 Finnish anthophyllite mines, Paakkila, Maljasalmi (Meurman et al,
1994)
903 82 N — 77 2.86 4 12.5 —
36 Vermiculite mine, Libby Montana, USA (contains tremolite)
(Sullivan, 2007)
1672 96 N 711 89 1.69 6 6.1 7.7
Abbreviations: A¼ adjusted; C¼ smoking prevalence in cohort comparable to the general population; N¼ none or not mentioned; SMR¼ standardised mortality ratio. aPleural
mesothelioma only. bThe two mesotheliomas were in men who were employed before 1936 when exposure to crocidolite was likely. cDeaths 20 years after first employment
only. dFour cancers of pleura and four mesothelioma (the latter only available from 1999 with ICD10). The four mesotheliomas were in workers who had been employed in plant 4,
where there was no record of amphibole use. Three pleural cancers were in plant 3, but these workers had not worked in the insulation section of plant 3, where amosite was used.
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Crocidolite and crocidolite plus chrysotile In the six crocidolite-
exposed cohorts, workers experienced increased lung cancer
mortality, of the order of a two-to three-fold increase (pooled
SMR 2.0, Table 3), and increased mesothelioma risk, with
mesothelioma deaths contributing to a median of 93.2 per
thousand deaths (range 23–217). In all but two smaller cohorts,
there were less or equivalent numbers of excess lung cancers
compared with mesothelioma deaths, giving a combined R1
estimate of 0.71 ARLC deaths per mesothelioma death (Table 3,
Figure 2). The combined estimate of ratio R2 suggests a 1.2%
increase in lung cancer deaths (PAF¼ 1.2%) associated with
crocidolite for every mesothelioma death in 1000 deaths.
For cohorts with a mixture of chrysotile and some crocidolite,
mesothelioma risk was also raised but to a lesser extent than for
pure crocidolite (7.6 mesothelioma deaths per 1000 non-asbestos-
related deaths). Lung cancer risk was increased (SMR 1.58),
varying from no lung cancer excess in the Ferodo friction factory
(estimate 12) to increases of over three-fold (Table 1 and
Figure 2). These combined to give an overall R1 estimate of 1.44
excess lung cancers per mesothelioma death (Table 3).
Chrysotile Chrysotile cohorts had a wider range of estimates,
resulting from little correlation between excess lung cancers and
mesotheliomas (Figures 1 and 2). Almost all SMRs for lung cancer
were between 1 and 2, with two notable exceptions of two Chinese
mines (estimates 25 and 29). In 14 of 16 estimates, the number of
excess lung cancer deaths was more than the number of meso-
thelioma deaths (Figure 2); an average R1 of 6.1 excess lung cancers
per mesothelioma death (Table 3). This much larger ratio, compared
with that for crocidolite, arises mainly from a much smaller
associated mesothelioma risk, including four cohorts that had
no mesothelioma deaths (estimates 17, 18, 28 and 29, Table 1).
Table 2 Cohorts with exposure to mixed asbestos fibres: lung cancer and mesothelioma mortality and ratio estimates
No. Cohort description (reference) N
%
Male
Smoking
adjustment
Total
deaths
Lung
cancer
deaths
(OLC)
Lung
cancer
SMR
Mesothelioma
deaths (OM)
Ratio
R1
Ratio
R2
Mixed (or unspecified) asbestos types
37 Belgian asbestos-cement factory (Lacquet et al, 1980) 1973 100 N 201 17 0.99 1 0.2 0.3
38 Devonport dockyard, UK (Rossiter and Coles, 1980) 6292 100 N 1043 84 0.84 31 0.5 0.5
39 Danish asbestos-cement factory (Clemmesen and Hjalgrim-Jensen,
1981)
6372 100 N — 47 1.72 3 6.6 —
40 Pennsylvania textile, USA. Mostly chrysotile, some amosite, small
amounts crocidolite (McDonald et al, 1983)
4137 100 N 1392 57 1.05 13 0.2 0.5
41 Ontario cement workers, Canada (Finkelstein, 1984) 535 100 N 108 26 4.89 17 1.2 1.6
42 Swedish rail maintenance (Ohlson et al, 1984) 3297 100 N 925 37 1.16 5 1.0 3.0
43 Pearl Harbour naval shipyard, USA (Kolonel et al, 1985) 5191 100 C 668 122 1.09 8 1.2 0.7
44 Paray-Le-Monial cement factory, France (Alies-Patin and Valleron,
1985)
1506 100 N 206 12 2.18 4 1.6 5.8
German asbestos workers (Woitowitz et al, 1986) NS N
45 (a) Exposed before 1972 only 655 71 12 4.62 6 1.6 3.6
46 (b) Exposed before and after 1972 3070 185 26 1.70 6 1.8 2.0
47 Gothenburg shipyard, Sweden (Sanden and Jarvholm, 1987) 3787 100 N — 11 1.12 4 0.3 —
48 Mixed industry, Johns Manville retirees, USA (Enterline et al, 1987) 1074 100 N 944 77 2.71 8 6.1 20.2
49 Cement, New Orleans Plant 1, USA. Primarily chrysotile, irregular
use of amosite and crocidolite (Hughes et al, 1987)
1898 100 C 477 47 1.17 2 3.4 4.0
50 Finnish shipyard workers (Tola et al, 1988) 7775 100 C — 227 1.18 1 34.9 —
51 Southern Sweden cement workers (Albin et al, 1990) 1465 100 N 592 35 1.80 13 1.2 3.5
52 Asbestos insulation union, USA–Canada (Selikoff and Seidman,
1991)
17 800 100 N 4951 1168 4.35 458 2.0 2.6
53 Italian rail carriage construction (Menegozzo et al, 1993) 1534 100 N 194 28 1.45 5 1.7 1.6
54 Emilia Romagna cement factory, Italy. Chrysotile and 5–50%
crocidolite (Giaroli et al, 1994)
3341 100 N 274 33 1.24 6 1.1 1.1
55 Danish Eternit cement factory, 90% chrysotile, amosite and small
amounts crocidolite (Raffn et al, 1996)
7996 100 C 1305 104 1.83 10 4.7 10.3
56 East London asbestos workers UK (Berry et al, 2000) of which: 5100 N 1237 233 3.03 100 1.6 2.0
57 As for 56: East London laggers 1400 100 N — 38 3.67 13 2.1 —
58 As for 56: East London men 3000 100 N — 157 2.55 60 1.6 —
59 As for 56: East London women 700 0 N — 37 7.46 25 1.3 —
60 Genoa shipyard, Italy (Puntoni et al, 2001) 3984 100 C 2376 298 1.77 60 2.2 2.8
61 Lithuania cement, Naujoji Akmeme Lithuania (Smailyte et al, 2004) 2498 69 N 450 38 1.40 1 10.9 17.5
62 Ontario pipe trade, Canada (Finkelstein and Verma, 2004) 25 285 100 N 2876 393 1.23 8 9.1 8.0
63 US Coast Guard shipyard workers (Krstev et al, 2007) 4702 94 N 3331 314 1.26 6 11.0 14.4
64 Grugliasco textile Italy. Mixed asbestos with crocidolite (Pira et al,
2007)
1966 45 N 730 109 3.11 68 1.1 1.8
65 Breda Pistoia railway rolling factory, Italy (Gasparrini et al, 2008) 1146 100 N 1080 132 1.36 16 2.2 2.3
Great Britain Asbestos Survey (Harding, 2010)
66 Men 94 403 100 C 14 677 1802 1.28a 631 0.6 0.6
67 Women 4509 0 880 84 1.29a 18 1.1 1.4
68 Japanese shipyard (laggers and boiler repairers) (Tomioka et al,
2011)
249 100 C 158 15 1.97 1 7.4 14.5
Abbreviations: A¼ adjusted; C¼ smoking prevalence in cohort comparable to the general population; N¼ none or not mentioned; SMR¼ standardised mortality ratio.
aProportional mortality ratio reported rather than SMR.
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The small denominator and wide range makes ratio estimates of
excess lung cancers to mesotheliomas large, but imprecise for
chrysotile.
Amphiboles In the follow-up of four amosite cohorts, there was a
marked correlation between lung cancer SMR and mesothelioma.
The combined SMR for lung cancer was 2.5, slightly stronger than
that for crocidolite and thus, with a mesothelioma risk approxi-
mately one-fifth of that for crocidolite (18 vs 93 mesotheliomas per
1000 deaths in amosite and crocidolite, respectively, Table 3), ratio
R1 was much higher at 4 excess lung cancers per mesothelioma
death (Table 3). Corresponding R2 estimates suggest there was
between a 6% and 10% increase in lung cancer deaths for every
mesothelioma death in 1000 deaths. The largest contributing study
was the Paterson amosite factory in New Jersey (estimate 32),
where both a large number of mesotheliomas (17 in 820 workers)
and a very large excess lung cancer mortality were observed
(SMR 4.8) (Seidman et al, 1986). In the only cohort with
anthophyllite exposure (estimate 35), there were 12.5 excess lung
cancers per mesothelioma death (Meurman et al, 1994).
Mixed asbestos types For the majority of cohorts asbestos
exposure was mixed and their ratio estimates lay between the
corresponding values for pure asbestos fibres. The summary SMR
for lung cancer was 1.77 (95% CI 1.44, 2.20), which was less than
that for crocidolite or amosite, but larger than that for chrysotile.
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Figure 1 (A) Ratio 1 components, absolute excess lung cancer excess deaths vs mesothelioma deaths, by asbestos type. (B) Ratio 2 components, lung
cancer excess relative risk (%) vs mesothelioma deaths per 1000 non-asbestos-related deaths, by asbestos type. Note that graphs are not to the same scale.
The reference line on each sub-graph corresponds to the same ratio estimate (average values for mixed fibres from Table 3); thus, the distribution of points
about this line can be compared across subgraphs.
Table 3 Estimated ratios by asbestos fibre type for (i) absolute excess lung cancer deaths to mesothelioma deaths and (ii) excess lung cancer percentage
to mesothelioma deaths per 1000 non-asbestos-related deaths
Lung cancer
mortality SMR
Ratio R1 excess lung cancers
per mesothelioma death
Ratio R2 excess lung cancer (%)
for every mesothelioma death in
1000 non-asbestos-related deaths
Asbestos type
(no. of estimates) Mean (95% CI)
Mesothelioma deaths per 1000
non-asbestos-related deaths Median (IQR) Mean (95% CI) Median (IQR) Mean (95% CI)
Crocidolite (6) 2.04 (1.55, 2.69) 93.2 0.7 (0.5, 1.1) U 0.7 (0.5, 1.0) 1.2 (0.9, 2.6) U 1.4 (1.0, 2.1)
SA 0.6 (0.3, 0.9) SA 1.2 (0.8, 1.8)
Chrysotile and
Crocidolite (8)
1.58 (1.19, 2.08) 7.6 1.7 (0.4, 6.8) U 1.4 (0.6, 3.5) 3.4 (0.4, 9.4) U 2.8 (1.0, 7.5)
SA 1.2 (0.5, 2.9) SA 2.4 (0.9, 6.3)
Chrysotile (16) 1.68 (1.39, 2.03) 4.1 8.2 (1.5, 11.0) U 6.1 (3.6, 10.5) 9.1 (3.6, 10.3) U 10.2 (5.5, 18.9)
SA 4.9 (2.8, 8.7) SA 8.3 (4.3, 15.9)
Amosite (4) 2.48 (1.42, 4.33) 18.6 4.1 (2.3, 5.3) U 4.0 (2.8, 5.8) 6.8 (5.8, 10.2) U 8.4 (5.9, 11.8)
SA 3.0 (2.1, 4.4) SA 6.3 (4.5, 8.8)
Mixed (31) 1.77 (1.44, 2.20) 42.2 1.6 (1.1, 4.4) U 1.9 (1.4, 2.6) 2.0 (1.2, 4.9) U 2.8 (1.9, 4.2)
SA 1.5 (1.1, 2.0) SA 2.2 (1.6, 3.2)
Abbreviations: CI¼ confidence interval; IQR¼ interquartile range (25th, 75th percentiles); SA¼ smoking adjusted; U¼ unadjusted. Means and their 95% CI calculated
from a random effects meta-analysis. I2 percentages (% of variability this is due to between-study difference) (heterogeneity P-value) for crocidolite, chrysotile+crocidolite,
chrysotile, amosite and mixed fibres, respectively, are: for unadjusted R1: 29% (P¼ 0.22), 85% (Po0.01), 53% (P¼ 0.007), 0% (P¼ 0.39), 94% (Po0.001); for R2: 52% (P¼ 0.06),
81% (Po0.001), 74% (Po0.001), 0% (P¼ 0.68), 97% (Po0.001).
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Mesothelioma deaths as a proportion of total mortality were half
that for crocidolite, but higher than chrysotile or amosite (Table 3).
There were between one and three excess lung cancers for every
mesothelioma death in half of the cohorts, but the estimate in the
two largest cohorts were very different, at 0.6 in men in the Great
Britain Asbestos Survey and 2.0 in US and Canadian insulation
workers (estimates 55 and 66, Table 1). For all mixed asbestos
cohorts combined, there were 1.9 (95% CI 1.4, 2.6) excess lung
cancer deaths for every mesothelioma death, although with large
heterogeneity.
Comparison of the two ratio estimates The percentage of the
variance explained by regression of the contributing numerator on
denominator was higher for R1 (495%) than for R2 for crocidolite,
crocidoliteþ chrysotile and for mixed asbestos cohorts, but was
higher for R2 than R1 for chrysotile and amosite cohorts.
Crocidolite
2 – Nottingham gas masks
1 – Canada gas mask canisters
Estimate number (see Tables 1 and 2)
0.34 (0.16, 0.70)
Ratio 1 (95% CI)
0.51 (0.19, 1.37)
4 – South Africa crocidolite
6 – Wittenoom mine/mill Australia
5 – Tuscany rail
3 – Leyland gas masks
Crocidolite and chrysotile
12 – Ferodo friction
13 – North Israel cement
11 – Vocklabruck cement
14 – Norway cement
7 – Rochdale men early cohort
0.69 (0.38, 1.22)
0.78 (0.65, 0.93)
1.00 (0.38, 2.60)
1.36 (0.48, 3.81)
0.71 (0.53, 0.94)
0.20 (0.00, .)
0.33 (0.19, 0.57)
0.50 (0.18, 1.39)
1.24 (0.70, 2.21)
2.06 (0.87, 4.86)
9 – Rochdale principle cohort
10 – New Orleans plant
8 – Rochdale women
Chrysotile
16 – Wales cement
19 – Tamworth cement
20 – Balangero mine
15 – Blackburn gas masks
21 – Quebec asbestos factory
22 – Thetford company 3
23 – Thetford company 4
2.87 (1.55, 5.31)
8.17 (3.01, 22.18)
50.00 (0.00, .)
1.44 (0.59, 3.49)
No excess lung cancers
1.05 (0.25, 4.47)
1.20 (0.14, 9.97)
2.48 (0.99, 6.22)
4.14 (2.66, 6.45)
4.90 (1.16, 20.69)
24 – Quebec asbestos mine
17 – Chongqin asbestos workers
30 – Chrysotile textile workers China
27 – North Carolina textile
26 – South Carolina textile
17 – Connecticut friction
18 – Sweden cement
28 – Greece asbestos cement
29 – Chrysotile miners China
Amosite
33 – South Africa amosite mines
7.11 (3.52, 14.38)
9.35 (2.20, 39.76)
10.45 (2.54, 43.05)
16.91 (8.37, 34.16)
32.17 (10.29, 100.59)
No mesothelioma deaths
6.12 (3.58, 10.45)
34 – Tyler pipe insulation
32 – Paterson amosite
31 – Uxbridge insulation
Subtotal  (I 2= 0.0%, P = 0.393)
Mixed
37 – Belgium cement
38 – Devonport dockyard
40 – Pennsylvania textile
47 – Gothenburg shipyard
66 – GB asbestos survey men
42 – Swedish rail maintenance
3.73 (1.57, 8.88)
4.56 (2.72, 7.63)
5.58 (2.24, 13.92)
4.04 (2.79, 5.87)
No excess lung cancers
0.21 (0.11, 0.38)
0.30 (0.10, 0.94)
0.63 (0.58, 0.69)
1.80 (0.63, 5.16)
1.04 (0.41, 2.65)
67 – GB asbestos survey women
54 – Emilia Romagna cement
64 – Grugliasco textile
51 – Southern Sweden cement
41 – Ontario cement
43 – Pearl Harbour naval shipyard
59 – East London women
45 – German asbestos workers (a)
58 – East London men
44 – Paray-Le-Monial
53 – Italian rail
46 – German asbestos workers (b)
1.05 (0.63, 1.75)
1.07 (0.45, 2.55)
1.09 (0.80, 1.47)
1.20 (0.63, 2.27)
1.22 (0.66, 2.24)
1.23 (0.60, 2.50)
1.28 (0.77, 2.13)
1.57 (0.59, 4.17)
1.59 (1.18, 2.14)
1.63 (0.52, 5.04)
1.74 (0.67, 4.51)
1.78 (0.73, 4.33)
52 – Asbestos insulation union
57 – East London laggers
60 – Genoa shipyard
65 – Breda Pistoia railway
49 – New Orleans Plant 1
55 – Denmark Eternit cement
48 – Johns Manville retirees
39 – Danish cement
68 – Japan shipyard
62 – Ontario pipe trade
61 – Lithuania cement
63 – US Coast Guard shipyard
50 – Finnish shipyards
2.12 (1.13, 3.99)
2.15 (1.63, 2.84)
2.18 (1.30, 3.66)
3.40 (0.83, 14.00)
4.71 (2.46, 9.01)
6.07 (2.93, 12.58)
6.57 (2.04, 21.10)
7.40 (0.98, 56.02)
9.11 (4.53, 18.35)
10.90 (1.50, 79.39)
10.95 (4.88, 24.56)
34.90 (4.89, 248.83)
1.96 (1.76, 2.19)
Subtotal  (I2= 93.6%, P<0.001) 1.89 (1.38, 2.58)
10.25 0.5 2 3 5 10 35
Ratio 1 = Excess lung cancer deaths to every mesothelioma death
Subtotal  (I2= 29.0%, P = 0.218)
Subtotal  (I2= 85.3%, P<0.001)
Subtotal  (I 2= 53.1%, P = 0.007)
Figure 2 Ratio of asbestos-related lung cancers to mesothelioma deaths, study-specific and random effects combined estimates by asbestos fibre type.
Estimates of the ratio of excess lung cancer deaths to every mesothelioma death (R1) in each study, by asbestos fibre type. I
2 represents the percentage of
the variation in the study-specific estimates that are due to true heterogeneity rather than due to chance.
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Population attributable fractions in men
Table 4 provides, for 20 countries with large mesothelioma
proportional mortality, PAFs (%) of male lung cancer deaths due
to asbestos estimated using the crude and smoking-adjusted
estimates of ratios R1 and R2 for exposure to mixed asbestos fibres,
and smoking-adjusted ratios for crocidolite. The smoking adjust-
ment (derived from 20% higher cohort smoking prevalence than
the general population) is likely to underestimate ratios and PAFs,
and can be considered a lower limit. In the countries listed,
mesothelioma deaths ranged from 1 to 9 per 1000 deaths. If the
ratio of ARLC to mesothelioma deaths were exactly 1, then
mesothelioma deaths as a percentage of lung cancer deaths
(ranging from 1% to 9% for these countries) would be the PAF (%)
of lung cancer due to asbestos. For Australia, at the top of the table
with the highest percentage of deaths from mesothelioma, using
ratio estimates for crocidolite, we estimated that between 5.4% and
8.6% of lung cancer deaths in men are asbestos-related, based
on R1 and R2, respectively. Similarly in the United Kingdom,
New Zealand, South Africa and the Netherlands, where crocidolite
was used among other asbestos fibres, PAFs ranged between
4% and 7%. For South Africa calculations based on R1 estimates
(PAF 6.7–8.4% for mixed fibres, 2.7% for crocidolite) are more
suitable as total background mortality, which is incorporated into
R2-based estimates, is particularly high in this country during the
HIV era. Applying the ratios for mixed asbestos exposures, PAFs
for other countries lie between 3% and 7% using both ratio methods
of estimation. For the United States, the estimated PAF in men was
estimated to be 3.2–4.0% for mixed asbestos (R1 estimates).
DISCUSSION
The ratios of ARLCs to mesotheliomas fall into three categories:
(1) pure amphibole or mixed exposures causing high lung cancer
risks and ARLC/mesothelioma ratios ranging from o1 for
crocidolite, 1.4 to 2.5 for mixed types, to 4 or more for amosite
and anthophyllite; (2) heavy prolonged chrysotile exposures causing
high lung cancer risks and ARLC :mesothelioma ratios of the order
of 10; and (3) shorter or less heavy chrysotile exposures causing
lower lung cancer risks and little mesothelioma, between which
there was little correlation and thus calculation of excess lung
cancers from mesothelioma deaths after chrysotile exposure would
not be reliable. Thus for all asbestos types other than crocidolite,
the ARLC is larger than that for mesothelioma, but the low ARLC
to mesothelioma ratio for crocidolite (0.71) does not imply that the
lung cancer risk is small, only that it is slightly smaller than the
high mesothelioma risk.
The ARLC :mesothelioma ratio in chrysotile cohorts may be domi-
nated by two large errors. First, the lung cancer excess depends
critically on the rates on which the SMR is based. Second, it seems
likely that many of the mesotheliomas in such cohorts are actually
due to amphibole exposure. These points are illustrated by the
chrysotile miners and millers in Quebec (estimates 21–24). Their
ARLC :mesothelioma ratio varied substantially, from 3.3 (22 meso-
theliomas; 423 lung cancers, SMR 1.21) for cumulative exposures
below 300 million particles per cubic foot (mpcf)-years to 31
(1 mesothelioma; 47 lung cancers, SMR 2.97) above 1000 mpcf-years.
The lung cancer excess above 1000 mpcf-years is affected little by
the choice of rates, but below 300 mpcf-years the lung cancer
excess could be doubled or reduced to zero by a 20% change in
expected rates. Furthermore, many mesotheliomas occurring in
asbestos that is predominantly chrysotile may actually be due to
other asbestos types. McDonald et al (1997) argued that the
mesotheliomas among chrysotile miners and millers in Quebec
were caused either by amphibole exposure elsewhere or by the
tremolite that contaminated most Canadian chrysotile. Analysis
of 22 lung samples from mesotheliomas in this cohort showed
that 6 contained substantial amounts of crocidolite, and only 2
contained more chrysotile than tremolite despite their much
heavier exposure to chrysotile. Tremolite, similarly to crocidolite
Table 4 Estimates of population attributable fractions (%) ranges of lung cancer in men due to exposure to mixed asbestos and crocidolite asbestos fibres
Population attributable fraction of lung
cancer due to asbestos, estimated for
No. of deathsa Mesothelioma deaths Mixed asbestos fibres
Crocidolite
Country
Lung
cancer Mesothelioma
Per 1000
all-cause deaths
% Of lung
cancer deathsb R1 1.5
c–1.9 R2¼ 2.2c–2.8 R1¼ 0.6c, R2¼ 1.2c
Australia 12 768 1156 7.8 9.1 13.6–17.2 14.7–18.0 5.4, 8.6
UK 90 347 7362 6.9 8.1 12.2–15.5 13.2–16.2 4.9, 7.7
New Zealand 3192 238 5.8 7.5 11.2–14.2 11.3–13.9 4.5, 6.5
Sweden 8386 491 3.2 5.9 8.8–11.1 6.5–8.1 3.5, 3.7
Netherlands 29 604 1629 6.2 5.5 8.3–10.5 12.0–14.8 3.3, 6.9
South Africa 2995 133 0.8 4.4 6.7–8.4 1.8–2.3 2.7, 1.0
Iceland 274 12 3.7 4.4 6.6–8.3 7.5–9.3 2.6, 4.2
Norway 5506 216 2.9 3.9 5.9–7.5 6.1–7.6 2.4, 3.4
Finland 6557 252 2.7 3.8 5.8–7.3 5.5–6.9 2.3, 3.1
Malta 528 20 3.3 3.8 5.7–7.2 6.8–8.4 2.3, 3.8
Denmark 1810 55 2.6 3.0 4.6–5.7 5.4–6.8 1.8, 3.0
Italy 24 126 729 3.4 3.0 4.5–5.7 7.0–8.7 1.8, 3.9
Germany 136 953 4102 2.7 3.0 4.5–5.7 5.5–6.9 1.8, 3.1
France 99 626 2900 2.9 2.9 4.4–5.5 5.9–7.4 1.7, 3.3
Luxembourg 690 16 2.3 2.3 3.5–4.4 4.8–6.0 1.4, 2.7
USA 413 529 8802 2.0 2.1 3.2–4.0 4.3–5.4 1.3, 2.4
Austria 8895 187 1.7 2.1 3.2–4.0 3.7–4.6 1.3, 2.0
Chile 6464 117 0.7 1.8 2.7–3.4 1.5–1.9 1.1, 0.8
Japan 185 988 3010 1.4 1.6 2.4–3.1 3.1–3.9 1.0, 1.7
Spain 76 606 978 1.4 1.3 1.9–2.4 2.9–3.6 0.8, 1.6
aBased on the number of mesothelioma deaths in 1000 deaths, men aged 40–84, years 2001–2005, for countries using ICD 10 (WHO mortality data). bNote that if
there were one asbestos-related lung cancer for every mesothelioma death, this percentage would be the PAF (%) of lung cancer due to asbestos. The ratio and thus PAFs
are likely to be higher. cCorrected for confounding by smoking of up to 20% higher cohort smoking rates compared with the general population.
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and amosite, is an amphibole that is cleared less rapidly from
the lung than chrysotile. The vermiculite miners in Montana
were included on this basis as vermiculite contains tremolite.
Nevertheless, irrespective of the contribution of tremolite, it seems
that prolonged heavy exposure to chrysotile causes a much larger
excess of lung cancer than of mesothelioma.
Heterogeneity in ratio estimates within and between
cohorts
Neither ratio R1 or R2 appeared to be more constant across all
cohorts. Although it was expected that R2 would more appro-
priately account for differential background lung cancer incidence
rates, and thus be a more constant ratio, its denominator – ideally
an age-adjusted mesothelioma mortality rate could not be
calculated – was mesothelioma proportional mortality and thus
was additionally affected by differential background mortality
rates. Nonetheless, PAF estimates using either ratio did not differ
hugely.
We have considered the effect of fibre type on ratios; however,
several other factors, discussed below, will affect within and
between study ratio estimates. Stratifying by each factor could not
be conducted owing to lack of data. The summary ratios provided
here thus better characterise the overall ARLC–mesothelioma
relationship across exposure circumstances and over a long period
of time, and do not serve to precisely quantify lung cancer excess
in a short time period.
(i) Dose–response relationship: Most formal risk assessment
analyses assume that the relative risk for lung cancer is
increased by each brief period of asbestos exposure in
proportion to dose (intensity times duration), whereas the
increase in the absolute mesothelioma rate is proportional to
the dose weighted by the square or cube of latency. Such
models imply that prolonged exposure beginning in middle
age will cause a ratio of ARLC to mesothelioma more than 10
times greater than brief exposure at age 20 years (Peto et al,
1985). The ratio is thus age-dependent and affected by
differences in the length of follow-up between studies.
Exposure intensity also varies between and within cohorts,
for example, if factory ventilation systems improve.
(ii) Death certificate reporting bias: Inaccurate recording of
deaths may lead to possible overestimation of ratios, as
shown by an autopsy-death certificate comparison in which
false-negative mesotheliomas were likely to be recorded as
lung cancers (Delendi et al, 1991). Special efforts to capture
all mesothelioma deaths from medical records and meso-
thelioma registries would have reduced this bias here and
mesothelioma-reporting accuracy should improve over time
with the use of ICD-10.
(iii) Overall mortality rates: Although the use of a relative effect
on lung cancer has been captured in R2, its denominator
would ideally be an age-standardised mesothelioma mortality
rate. Instead the mesotheliomas per 1000 deaths are affected
by changes in the overall risk of death. Mesothelioma
proportional mortality will be higher in cohorts with lower
mortality.
(iv) Confounding/effect modification by smoking and other lung
carcinogens: Ratio estimates hinge on the assumption that
SMRs for lung cancer are unbiased. Several cohorts specifi-
cally adjusted for smoking (estimates 11, 25, 29, 30, 68) and in
some others estimates of smoking prevalence in subsets
suggest that they were similar to that of the general population
(estimates 43, 50, 51). Use of the PMR (1.28) rather than the
SMR (1.89) for lung cancer was intended to reduce
confounding by smoking (estimates 66, 67; Harding, 2010).
The extent to which bias may be present in other cohorts
depends on the social-class smoking gradient. Two recent
cohorts commented on a higher smoking prevalence (esti-
mates 61, 62) than in the general population, which may
explain their high ratios. In addition, asbestos has a stronger
effect on lung cancer in smokers than non-smokers, whereas
smoking has little or no effect on mesothelioma. Thus, higher
baseline lung cancer mortality rates may explain the higher
ratios observed in United States and the European cohorts
than in Israel (estimate 13, with a low lung cancer mortality
rate; Tulchinsky et al, 1999). The great majority of cohorts
included here were from Europe, the United States and
Canada, where asbestos exposure occurred predominantly
during the 1940s to 1970s when smoking prevalence was high.
Estimates for Ontario pipe traders and two cohorts of
shipyard workers (cohorts 50 and 63) may be overestimated
if these workers also had exposure to other lung carcinogens,
such as lead, chromium, cadmium and diesel exhaust.
Population-level inferences
For countries with the highest percent deaths from mesothelioma
in men, estimates of the lung cancer PAF due to asbestos were
between 3% and 8% for 2001–2005. In almost all of these
countries, lung cancer made up 20–30% of cancer deaths, thus
even 3–8% of this is a considerable contribution to the most
common cause of cancer mortality in men in these settings.
A few previous lung cancer-asbestos PAF estimates have been
made. For the United Kingdom, the British Asbestos Survey
included here had an R1 value of 0.6, much lower than the other
mixed asbestos cohorts. Darnton et al (2006) obtained a similar
estimate (R1 between 0.7 and 1) from a population-based analysis
of the relationship between lung cancer and mesothelioma PMRs
in men in 131 occupational groups, adjusting for smoking, and a
PAF of 2% to 3%. This is approximately half of the estimate found
here (4.9% to 7.7% using crocidolite ratios, from Table 3), and the
difference may be because their estimate was for a longer earlier
period (1980–2000) than the current estimates (for 2001–2005),
during which time mesotheliomas have increased as a percentage
of lung cancer deaths (from 3.8% to 8.1%). However, as amosite
was a major cause of mesothelioma in the United Kingdom (Rake
et al, 2009), the lung cancer excess in the United Kingdom would
be expected to be even higher. For Italy, Marinaccio et al (2008)
used a model-based approach to estimate the ARLC burden in men
in 1980–2001 and found PAFs for lung cancer mortality of
between 1.6% and 3.7%, that is, a ratio (R1) of between 0.68 and
1.37 excess lung cancers per mesothelioma. These estimates are
similar to those of Darnton et al (2006), and also suggest a slightly
lower ratio of ARLCs to mesotheliomas than that based on our
estimated ratios from mixed asbestos cohorts. In the United States,
where amphiboles constituted a much smaller proportion of
asbestos consumption than in Europe, estimates of the male lung
cancer PAF for asbestos were 6% to 8% in the 1990s (Nicholson
et al, 1982; Morabia et al, 1992), slightly higher than the estimate of
4.0–5.0% here. In Finland, where anthophyllite was mined
extensively, 2.7 mesothelioma deaths per 1000 would lead to a
PAF for lung cancer of over 11% (using R2¼ 4.4), consistent with
Nurminen and Karjalainen (2001) estimate of 14%. Attempts to
estimate ARLCs at a population level should be made with
additional caveats. The majority of asbestos exposures at the
population level may be of lower intensity and for longer
durations, and the largest exposed groups may not be represented
in asbestos cohorts, for example, construction workers and
carpenters in the United Kingdom (Rake et al, 2009).
The asbestos-related cancer burden today is predominantly in
Europe, North America, Australia, Japan, South Africa and parts of
South America. However, the highest current consumption and
exposure, and thus future burden, is in China, Russia, India,
Kazakhstan, Ukraine, Thailand, Brazil and Iran. Exposure today is
predominantly to chrysotile, either in a pure form or naturally
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contaminated by tremolite. The ratios presented demonstrate that
the mesothelioma-producing potential of chrysotile is low and thus
the number of mesothelioma deaths will be too unstable to be
used to estimate the lung cancers caused by it. Critically, few
mesotheliomas associated with chrysotile exposure cannot be used
to imply a small asbestos-related lung cancer burden. The major
effect of the continuing use of this carcinogen will be on lung
cancer. High smoking rates in men (e.g., 70% in Russia, 61% in
China (World Health Organization, 2008)) in these countries will
amplify the associated lung cancer burden. There is thus an urgent
need for limiting exposure through strict regulation of asbestos
use, and encouragement of smoking cessation to reduce mortality
among formerly exposed workers.
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